Anagram is a clinical stage company leveraging proprietary enzyme technologies and expertise in gastrointestinal diseases to solve complex problems and advance a pipeline of products that can make a life-changing impact for people and their families living with cystic fibrosis and other rare diseases. Malabsorption syndromes and nutrient metabolism disorders prevent the body from properly processing or absorbing certain fats, sugars, proteins, vitamins or other key nutrients. ANG003, Anagram’s lead product is intended for the treatment of malabsorption and exocrine pancreatic insufficiency and is a new class of broad-spectrum digestive enzyme replacement therapy.